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Summary Tumour growth rates were measured in 105 patients using in vivo incorporation of bromodeoxy-
uridine (BrdU) and investigated for any relationship to tumour factors or survival. The median labelling
index (LI) was 8.7%, the duration of S-phase (Ts) was 14 h and the potential doubling time (Tpo) was 5.9
days. The labelling index in aneuploid tumours was significantly higher than that in diploid tumours. However
the total labelling index (TLI) did not differ significantly between aneuploid and diploid tumours, and so it
would seem likely that the difference in LI is due to the dilutional effect of benign tissue upon the calculation
of LI in diploid tumours. The total labelling index, duration of S-phase and potential doubling time were not
related to the tumour factors examined (site, T stage, N stage, stage grouping). Interim survival analysis was
carried out and there was no difference in survival between those patients with high values for TLI, Ts, and
Tpo, and those with low values.
Patients with head and neck cancer have varying clinical
courses, different responses to treatment and, as many
patients present with advanced disease, a relatively poor
prognosis. It has been suggested that measurement of cell
kinetics in human tumours might provide prognostic inform-
ation and allow prediction of response to radiotherapy or
chemotherapy. We have evaluated this in part using the
incorporation of bromodeoxyuridine into DNA as a marker
of cell proliferation.
The general approach to measuring cell kinetics is to iden-
tify a 'window' in the cell cycle and measure the movement
of a particular cohort ofcells through this window. BrdU, an
analogue of thymidine, is incorporated into cells during the
S-phase of the cell cycle. BrdU is non-toxic and non-radio-
active and can be given intravenously to human patients.
Infusions of BrdU at higher dosage can be tolerated for
several weeks without severe myelosuppression (Mitchell et
al., 1983; Kinsella et al., 1984) and there have been no
reports of toxic reactions in any patients receiving BrdU at
200 mg m2. It is taken up by the tumour, and the propor-
tion of cells that have taken up BrdU can be detected using
monoclonal antibodies. Furthermore, a pulse label of BrdU
can be given approximately 6 h before biopsy or excision of
the tumour, allowing the length of S-phase to be calculated
(Begg et al., 1985). The simultaneous measurement of BrdU
and DNA content using flow cytometry enables several cell
kinetic parameters to be quantified. We have previously
reported upon the cell kinetic results in 82 tumours and
demonstrated their reproducibility (Forster et al., 1992).
In this study we present further cell kinetic data on 105
patients with squamous cell tumours of the head and neck
and investigate the relationship to tumour stage, site and
prognosis.
Method
Patients studied
Ninety patients were treated in the Royal Liverpool Hospital
and 15 patients in hospitals in Glasgow between August 1988
and April 1992. The tumours were staged using the UICC
(1984) method and performance status assessed using the
ECOG method (AJC, 1972). Patient characteristics are
shown in Table I. The median potential follow-up time was
11 months. These patients are part of an ongoing prospective
study and the survival data on these patients should be
viewed as an interim report. The majority of patients studied
were undergoing major ablative surgery with curative intent.
Forty-one patients had recurrent disease and had received
previous treatment, largely with radiotherapy (DXT).
BrdU dosage and administration
A single dose of 200 mg of freeze-dried BrdU in 20 ml of
0.9% saline was administered as an intravenous bolus. Three
to 16 h later a biopsy or surgical excision was performed and
the sample fixed in 70% ethanol and stored at 4°C until
processing.
Flow cytometry
The flow cytometry methods of preparation and analysis
have been described in detail previously (Forster et al., 1992).
Table I Patient characteristics
Host factors
Sex
Male
Female
Age
Mean
Range
ECOG status
0
1
2
3
Site of primary tumour
Hypopharynx
Larynx
Oropharynx
Oral cavity
Ear
Nose and sinus
Salivary gland
Unknown primary
Treatment received
Surgery alone
Surgery and post-operative DXT
Surgery and chemotherapy
DXT
DXT and chemotherapy
Palliative treatment
86
19
62.1 years
39-91
80
23
0
2
42
24
16
13
5
3
1
1
43
42
6
2
1
11
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In brief, tumour samples were minced as finely as possible
with a scalpel and disaggregated into nuclei using 0.5%
pepsin pH 1.5 at 37C for 30 min. The DNA was denatured
with 2 M hydrochloric acid for 30 min at room temperature.
The nuclear suspension was then incubated with mouse anti-
BrdU (Dako, High Wycombe, UK) at a dilution of 1:30 for
1 h at room temperature, washed and incubated with goat
anti-mouse IgG fluorescein isothiocyanate-conjugated
antibody (Sigma Chemical, Poole, UK) for 30 min at room
temperature at a dilution of 1:40. Total DNA was stained
using 10 ig ml-' propidium iodide and the samples analysed
using a Coulter Epics Profile II flow cytometer.
The data derived from the flow cytometric profiles were
the DNA ploidy, labelling index (LI) and the total labelling
index (TLI). The Ts was derived using the method of Begg et
al. (1985) and the Tpot using the formula:
Tpot = A x Ts/LI
where A was assumed to be 0.8 (Steel, 1977).
The method by which a labelling index can be measured in
diploid tumours is slightly different from that in aneuploid
tumours. In the latter case the LI of tumour nuclei alone can
usually be obtained, whereas in diploid tumours the tumour
nuclei are mixed with an unknown quantity of nuclei from
normal tissue. An alternative method of comparing the LI in
diploid and aneuploid tumours is to use the TLI, which
measures the number of labelled nuclei in the whole sample,
and hence the dilutional effect from normal nuclei occurs in
both tumour types.
Tumourfactors and cell kinetic measurements
In order to determine whether there was any association
between tumour factors (site, stage grouping, tumour size
and nodal status) and cell kinetic parameters (TLI, Ts, Tpo)
each was examined in turn. The TLI was used in preference
to the LI as this was later shown to be associated with ploidy
status. Cell kinetic measurements were compared between the
four largest site groups.
Statistics
The results were analysed using a range of non-parametric
techniques. Rates and proportions were analysed using the
chi-squared test with Yates' correction where appropriate,
and associations between continuous and ordered variables
were assessed using the Spearman rank correlation co-
efficient. Survival curves were derived using Kaplan-Meier
estimates, and groups compared using the log-rank test (Peto
et al., 1977). Continuous variables were analysed using the
Mann-Whitney test when two groups were being compared,
or the Kruskal-Wallis test when more than two groups were
being compared. The results of these last two tests are
reported in terms of H, the appropriate x2 statistic.
Results
DNA ploidy and cell kinetic measurements
Ploidy and labelling index Out of the 105 patients studied,
29 tumours were diploid and 76 (72.3%) were aneuploid. The
median and range of kinetic data values for diploid and
aneuploid tumours are shown in Table II. The LI was
significantly higher in aneuploid tumours (H = 10.71, 1 d.f.,
P = 0.001). Using the TLI there was a tendency for aneu-
ploid tumours to be higher, but this was not statistically
significant (H= 2.07, 1 d.f., P = 0.151).
Ploidy and S-phase analysis The duration of S-phase was
very similar in both diploid and aneuploid tumours
(H = 0.03, 1 d.f., P = 0.872). The median duration of S-phase
was 14 h and the values for the first and third quartiles were
12.4 and 19.1 h. A small number of aberrant, unexplained
high values were obtained. The length of S-phase and the
Table II Median and range values of kinetic data for diploid and
aneuploid tumours
All Diploid Aneuploid
LI (%) 8.7 6.5 9.4
(1.6-25.1) (1.6-20.3) (3.7-25.1)
Total LI (%) 7.0 6.7 7.1
(1.3-21.9) (1.8-21.3) (1.3-21.9)
Ts (h) 14.0 14.8 13.9
(7.0-106) (7.8-71.5) (7.0-106)
Tpot (days) 5.9 7.0 5.6
(1.3-67.5) (2.8-40.9) (1.3-67.5)
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Figure 1 Overall mortality, high ( ) vs low (---) potential
doubling time.
labelling index were independent factors (Spearman rank
correlation = 0.01).
Ploidy and potential doubling time The Tpot for aneuploid
tumours was significantly shorter than that for diploid
tumours (H = 5.58, 1 d.f., P = 0.018), reflecting the higher
labelling index of these tumours. The median potential doub-
ling time was 5.9 days and the values for the first and third
quartiles were 4.3 and 8.1 days.
Tumourfactors and cell kinetic measurements
Site The site of the primary tumour and number ofpatients
are shown in Table I. Using the Kruskal-Wallis test no
systematic trend was seen for either TLI (H = 6.81, 3 d.f.,
P = 0.79), Ts (H = 5.38, 3 d.f., P = 0.147) or Tpot (H = 2.75,
3 d.f., P = 0.432).
Tumour size Ninety patients had disease present at the
primary site, of whom 82 could be staged, when their tumour
kinetics was measured. Nine patients had TI, 16 had T2, 27
had T3 and 30 had T4 disease. Cell kinetic measurements
were then compared between the groups. Using the Spear-
man rank correlation test no systematic trend was seen for
either TLI (P = 0.276), Ts (P = 0.433) or Tpot (P = 0.951).
Nodal disease Sixty-six patients had clinical evidence of cer-
vical lymph node metastases, 36 were node negative and in
three the nodal status was not known. Twenty-one patients
had N1, 32 had N2 and 13 had N3 disease. Cell kinetic
measurements were then compared between the groups.
Using the Spearman rank correlation test no systematic trend
was seen for either TLI (P = 0.915), Ts (P = 0.641) or Tpot
(P = 0.997).
Disease stage The majority of patients had advanced
disease. Two patients had stage I disease, 11 had stage II, 25CELL KINETICS AND TUMOUR FACTORS IN HEAD AND NECK CANCER 719
had stage III, 66 had stage IV and one patient could not be
staged. Cell kinetic measurements were then compared
between stages II, III and IV. Using the Spearman rank
correlation test no systematic trend was seen for either TLI
(P = 0.564), Ts (P = 0.701) or Tpo, (P = 0.441).
Fate At the time of this interim analysis 59 patients out of
the 105 remained alive and well. One patient was alive with
disease. Recurrent tumour had led to the death of 40
patients. Four patients had died of intercurrent disease and
one had died of a second tumour in the upper aerodigestive
tract. As the majority of deaths had been due to tumour only
the observed mortality rate was analysed.
Survival There was no significant difference between the
survival curves for patients with diploid and aneuploid
tumours (Q = 0.09, 1 d.f., P = 0.77). The relationship
between tumour kinetic data and survival was examined for
each of LI, TLI, Ts and Tp,1 The patients were divided into
those with values above the median and those with values
below the median. There was no significant difference in
survival between those patients with a high LI or TLI and
those with a low value (x2 = 0.01, 1 d.f., P = 0.92, and
X = 0.22, 1 d.f., P = 0.64, respectively). Neither was there
any significant difference in survival between those patients
with a long or short value for the duration of S-phase
(X2 = 0.28, 1 d.f., P = 0.60). In Figure 1 the survival curves
for patients with high and low values for potential doubling
time have been compared. There was no significant difference
between the two groups (X2 = 0.00, 1 d,f., P = 0.96). The 1
year mortality was 62% in those patients with a short poten-
tial doubling time and 60% in those with longer values. The
95% confidence interval for the difference ranged from
-19% to 23%.
Discussion
The TLI, Ts and Tpo, were not related to the tumour factors
examined (site, T stage, nodal status, stage grouping). This is
a prospective study and only interim survival data were
available. So far, there has been no observed difference in
survival between those patients with high values for TLI, LI,
Ts and Tpot and those with low values. The relatively small
size of the series and short follow-up times mean that the
lack of a difference in survival is not a very strong negative
finding as shown by the confidence intervals.
The growth fraction of a tumour has been estimated using
a variety of methods over the years. The use of tritiated
thymidine was one of the first. In a series of 52 oral cavity
carcinomas the mean thymidine labelling index was 11%,
ranging from 0.01% to 50% (Silvestrini et al., 1984).
Greenberg et al. (1988) studied seven patients with a
squamous carcinoma of the head and neck and found a
median thymidine labelling index of 3.7%. They also noted
considerable variability in multiple samples of the same
tumour, ranging from 0.2 to 23.7%.
Flow cytometric estimation of the proportion of cells in
S-phase has been performed by several groups. Ensley et al.
(1989) reported that three-quarters of 165 patients with
squamous carcinomas of the head and neck had an S-phase
fraction (SPF) above 15% and that there was a strong direct
correlation between DNA index and SPF. Franzen et al.
(1986) found a mean SPF of 6.4% in diploid tumours, 10%
in polyploid tumours and 19% in aneuploid tumours, with a
range of 1-30% amongst 24 oral cavity carcinomas. Johnson
et al. (1985) reported a mean SPF of 19% with a range of
4-45% in 45 patients with tumours at various sites within
the head and neck.
Using in vitro labelling of cells with bromodeoxyuridine
(Hemmer, 1990), the values obtained for S-phase varied from
0 to 23.2% with a median of 2.6% among 33 primary
previously untreated squamous cell carcinomas of the oral
cavity. In contrast, Hirano et al. (1991) using a different
method of in vitro bromodeoxyuridine labelling found a
mean LI of 22.9% with a range of 9.15-33.5% among 24
squamous carcinomas from various sites within the head and
neck region. The variation in LI reported between series
probably reflects problems with reproducibility of both flow
cytometric S-phase and in vitro BrdU methodologies, never-
theless the results of LI in this study fall within the range of
previous observations.
Two centres have published cell kinetic studies in a large
number of patients with a variety of malignancies using in
vivo administration of bromodeoxyuridine and flow cyto-
metry (Riccardi et al., 1988; Wilson, 1991). Their results are
similar to those in this series. Wilson found the duration of
S-phase in head and neck tumours to be slightly shorter than
our results (Table III), whereas the figures in this study are
closer to the values that they found in other types of tumour.
In a study of 100 colorectal carcinomas the median values for
LI, Ts and Tpo, were broadly similar to those found in
squamous carcinoma of the head and neck (Rew et al.,
1991).
We observed no relationship between any of the cell
kinetic parameters and tumour factors (site, stage grouping,
T stage and nodal status), which is in agreement with most
other studies (Hirano et al., 1991; Rew et al., 1991; Bennett
et al., 1992). However, in one reported series of 33 oral
cavity carcinomas, the LIs of T3 tumours were significantly
higher than those of TI and T2 carcinomas. There were also
significantly higher LIs in primary tumours with lymph node
metastases than in those without, but no difference as regards
subsite or histological grading (Hemmer, 1990). In a large
series of 123 head and neck carcinomas there was no rela-
tionship between proliferation parameters and site, histo-
logical grading, T staging or nodal status (Bennett et al.,
1992).
In the present study there was no relationship between any
of the cell kinetic parameters and an interim analysis of
survival data. There have been very few publications examin-
ing tumour growth rates and prognosis in tumours of the
head and neck region. Franzen et al. (1986) reported that the
mean SPF was higher (16.1%) in a small group of eight oral
cavity tumours eradicated by preoperative radiotherapy than
for 13 that did not respond (8.1%). In contrast, pretreatment
thymidine labelling index was not related to short- or long-
term response to radiotherapy in another series of 52 oral
cavity carcinomas, but a reduction of more than 70% in the
thymidine labelling index after the first 10 Gy was associated
with a good prognosis (Silvestrini et al., 1984). In a
preliminary evaluation of patients whose pretreatment cell
kinetics was assessed using bromodeoxyuridine and who were
in a pilot study of continuous, hyperfractionated, accelerated
radiation treatment (CHART) there was no significant
influence of any of the parameters measured (LI, Ts, Tpo,) on
local tumour control. Similar numbers of successes or failures
were observed above and below the median value for each
parameter (Wilson, 1991).
Publications examining tumour growth rates and prognosis
in other types of malignancy are more common, although
studies using in vivo bromodeoxyuridine to assess cell kinetics
are yet to appear. In 1989 Tubiana and Courdi reviewed a
large number ofstudies investigating the relationship between
survival and the percentage of tumour cells in S-phase
assessed by a variety of methods. They concluded that S-
phase fraction was ofhigh prognostic significance, particular-
ly in breast cancers, non-Hodgkin's lymphomas, ovarian
cancers, neuroblastoma, bladder and lung cancers. It is not
Table III A comparison of results for diploid and aneuploid head
and neck tumours
Reference Ploidy LI Ts TP0,
Wilson (1991) Diploid 3.9 8.9 8.0
This series Diploid 6.7 14.8 7.0
Wilson (1991) Aneuploid 9.3 11.5 4.2
This series Aneuploid 7.1 13.9 5.6720 L.D. COOKE et al.
clear whether they attempted a comprehensive review of all
publications up to 1988 when the manuscript was submitted,
but within the head and neck region they omitted the paper
by Franzen et al. (1986). Despite Tubiana and Courdi's
strong conclusion on the prognostic usefulness of SPF there
have been subsequent large series in both breast and ovarian
cancer which found no correlation between SPF and prog-
nosis (Conte et al., 1989; Cooke et al., 1992).
In conclusion, at present cell kinetic measurements are not
sensitive enough to be used clinically to predict prognosis.
However, the final results of several prospective studies in
different centres are awaited.
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